Drug Pricing
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Navigate global drug pricing strategies. Gain insights on PBMs, value-based pricing, and market access for pharma BD and investors.
Showing 1–12 of 16 articles
Quick answer
NovaPharmaNews Drug Pricing hub for FDA covers 16 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Medicare GLP-1 coverage 2026: Bridge program starts July 1
$2M Gene Therapy Cures Need a Financing Model
Pharmalittle: Roche accuses U.S. of 'blackmail,' Supreme Court rules on skinny labels
Supreme Court Upholds Medicare Drug Price Negotiation: Implications for Pharma
FDA's New Stance on Drug Pricing: Impact on Approvals and Pharma Strategy
altRx GLP-1 Review 2026: FDA Updates on Semaglutide
BBSW AI Solution Debuts for Biotech Research in the US
FDA Accelerated Approval Pathway: Impact on Oncology Market Access & Pricing in 2026
Regeneron Announces Free Gene Therapy Otarmeni for Rare Hearing Loss in U.S. Government Agreement
Inflation Reduction Act Drug Pricing: Impact on FDA Negotiations & Innovation 2026
Biosimilars Market Analysis: Impact of Recent FDA Approvals on US Pricing & Competition
FDA Biosimilar Approval Pathway: Key Regulatory Changes & Market Impact 2026
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.